At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 99 enrolled
Drug / intervention
Ofatumumabbiological
Likely dose
Ofatumumab 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-month, Open-label, Prospective, Multicenter, Interventional, Single-arm Study Assessing the Efficacy and Safety of Ofatumumab 20 mg Subcutaneous (s.c.) Injection in Relapsing Multiple Sclerosis (RMS) Patients in China
In Brief
A Phase 4 clinical trial evaluating Ofatumumab for Relapsing Multiple Sclerosis. Completed, enrolled 99 participants across 18 sites.
Detailed Summary
The purpose of this study was to evaluate the efficacy and safety of ofatumumab s.c. in adult participants with relapsing multiple sclerosis (RMS) in China.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing Multiple Sclerosis
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
20222023202420252026
First PostedJan 2022
Enrollment StartJul 2022
Primary CompletionFeb 2025
TodayJul 2026
First PostedJan 20, 2022
Enrollment StartJul 22, 2022
Primary CompletionFeb 13, 2025
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 4.5 years ago
Interventions
Ofatumumabbiological
Solution for injection in an autoinjector (pre-filled pen) containing 20 mg ofatumumab